Guiding Nurses On HCC Management During The Era Of COVID-19
This OncLive® webinar focused on the impact of COVID-19 on oncology nursing care for patients with hepatocellular carcinoma. We featured oncology nurse experts, Amy Hillsman, CRNP, and Abigail Smith, CRNP, discussing important topics and considerations for nurses and how they continue to provide the best care for their patients during this time.
Date: 5/18/2020 @ 8-9PM EDT
View the webinar here:https://event.on24.com/wcc/r/2335530/5180C656EBB5251DF2642D2B92988F9A
Description/Overview:
This OncLive® webinar will focus on the impact of COVID-19 on oncology nursing care for patients with hepatocellular carcinoma. We will feature oncology nurse experts, Amy Hillsman, CRNP, and Abigail Smith, CRNP, discussing important topics and considerations for nurses and how they continue to provide the best care for their patients during this time.
The following topics will reviewed:
· How COVID-19 has impacted oncology nurses taking care of patients with HCC
· Nursing involvement in symptom and adverse event management in patients with HCC during the COVID-19 pandemic
· Important topics and considerations for nurses including PPE shortages and the uptake of telemedicine
Faculty:
Abigail Smith
CRNP, Nurse Practitioner
University of Pennsylvania Perelman Center for Advanced Medicine
Amy Hillsman
CRNP, Nurse Practitioner
Georgetown Lombardi Comprehensive Cancer Center
Sponsored By: Bayer
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
Side Effects From Regorafenib May Lead to Discontinuation in uHCC With Poor Liver Function
January 21st 2024Treatment with regorafenib in patients with unresectable hepatocellular carcinoma and poor liver function may lead to serious side effects that may result in discontinuation of the treatment.
Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC
January 20th 2024Patients with advanced hepatocellular carcinoma treated with frontline pembrolizumab plus lenvatinib showed a 3-year or more response among 35% of responders, although additional efficacy results from the trial are consistent with previous findings from the phase 3 LEAP-002 trial.
